blinatumomab,inotuzumab
pfizer,amgen,ucb pharmaceuticals,astellas
['bet', 'blinatumomab', 'inotuzumab']
congress|#ash22 dr matthias stelljes, reports the gmall-initial1 trial results on inotuzumab ozogamicin induction, followed by standard chemo in pts aged &gt;55 yrs with nd ph neg bcp-all. primary endpoint was met; high remission rates and low toxicities observed. 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm